Read news on Hgtia - EurekAlert with our app.
Read more in the app
Insilico completes first-in-human dosing in phase I clinical study of AI-driven NLRP3 inhibitor ISM8969, achieving first clinical milestone in collaboration with Hgtia - EurekAlert!
